Chimeric Antigen Receptor T Cell-Mediated Neurotoxicity in Nonhuman Primates. 2018

Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
The Ben Towne Center for Childhood Cancer Research, Seattle Children's Research Institute, Seattle, Washington.

Chimeric antigen receptor (CAR) T-cell immunotherapy has revolutionized the treatment of refractory leukemias and lymphomas, but is associated with significant toxicities, namely cytokine release syndrome (CRS) and neurotoxicity. A major barrier to developing therapeutics to prevent CAR T cell-mediated neurotoxicity is the lack of clinically relevant models. Accordingly, we developed a rhesus macaque (RM) model of neurotoxicity via adoptive transfer of autologous CD20-specific CAR T cells. Following cyclophosphamide lymphodepletion, CD20 CAR T cells expand to 272 to 4,450 cells/μL after 7 to 8 days and elicit CRS and neurotoxicity. Toxicities are associated with elevated serum IL6, IL8, IL1RA, MIG, and I-TAC levels, and disproportionately high cerebrospinal fluid (CSF) IL6, IL2, GM-CSF, and VEGF levels. During neurotoxicity, both CD20 CAR and non-CAR T cells accumulate in the CSF and in the brain parenchyma. This RM model demonstrates that CAR T cell-mediated neurotoxicity is associated with proinflammatory CSF cytokines and a pan-T cell encephalitis.Significance: We provide the first immunologically relevant, nonhuman primate model of B cell-directed CAR T-cell therapy-mediated CRS and neurotoxicity. We demonstrate CAR and non-CAR T-cell infiltration in the CSF and in the brain during neurotoxicity resulting in pan-encephalitis, accompanied by increased levels of proinflammatory cytokines in the CSF. Cancer Discov; 8(6); 750-63. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 663.

UI MeSH Term Description Entries
D008253 Macaca mulatta A species of the genus MACACA inhabiting India, China, and other parts of Asia. The species is used extensively in biomedical research and adapts very well to living with humans. Chinese Rhesus Macaques,Macaca mulatta lasiota,Monkey, Rhesus,Rhesus Monkey,Rhesus Macaque,Chinese Rhesus Macaque,Macaca mulatta lasiotas,Macaque, Rhesus,Rhesus Macaque, Chinese,Rhesus Macaques,Rhesus Macaques, Chinese,Rhesus Monkeys
D011948 Receptors, Antigen, T-Cell Molecules on the surface of T-lymphocytes that recognize and combine with antigens. The receptors are non-covalently associated with a complex of several polypeptides collectively called CD3 antigens (CD3 COMPLEX). Recognition of foreign antigen and the major histocompatibility complex is accomplished by a single heterodimeric antigen-receptor structure, composed of either alpha-beta (RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA) or gamma-delta (RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA) chains. Antigen Receptors, T-Cell,T-Cell Receptors,Receptors, T-Cell Antigen,T-Cell Antigen Receptor,T-Cell Receptor,Antigen Receptor, T-Cell,Antigen Receptors, T Cell,Receptor, T-Cell,Receptor, T-Cell Antigen,Receptors, T Cell Antigen,Receptors, T-Cell,T Cell Antigen Receptor,T Cell Receptor,T Cell Receptors,T-Cell Antigen Receptors
D003520 Cyclophosphamide Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer. (+,-)-2-(bis(2-Chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-Oxide Monohydrate,B-518,Cyclophosphamide Anhydrous,Cyclophosphamide Monohydrate,Cyclophosphamide, (R)-Isomer,Cyclophosphamide, (S)-Isomer,Cyclophosphane,Cytophosphan,Cytophosphane,Cytoxan,Endoxan,NSC-26271,Neosar,Procytox,Sendoxan,B 518,B518,NSC 26271,NSC26271
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014182 Transplantation, Autologous Transplantation of an individual's own tissue from one site to another site. Autografting,Autologous Transplantation,Autotransplantation,Autograftings,Autologous Transplantations,Autotransplantations,Transplantations, Autologous
D016219 Immunotherapy, Adoptive Form of adoptive transfer where cells with antitumor activity are transferred to the tumor-bearing host in order to mediate tumor regression. The lymphoid cells commonly used are lymphokine-activated killer (LAK) cells and tumor-infiltrating lymphocytes (TIL). This is usually considered a form of passive immunotherapy. (From DeVita, et al., Cancer, 1993, pp.305-7, 314) Adoptive Cellular Immunotherapy,Adoptive Immunotherapy,CAR T-Cell Therapy,Cellular Immunotherapy, Adoptive,Chimeric Antigen Receptor Therapy,Immunotherapy, Adoptive Cellular,Adoptive Cellular Immunotherapies,Adoptive Immunotherapies,CAR T Cell Therapy,CAR T-Cell Therapies,Cellular Immunotherapies, Adoptive,Immunotherapies, Adoptive,Immunotherapies, Adoptive Cellular,T-Cell Therapies, CAR,T-Cell Therapy, CAR,Therapies, CAR T-Cell,Therapy, CAR T-Cell
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D018951 Antigens, CD20 Unglycosylated phosphoproteins expressed only on B-cells. They are regulators of transmembrane Ca2+ conductance and thought to play a role in B-cell activation and proliferation. CD20 Antigens,CD20 Antigen,Antigen, CD20

Related Publications

Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
December 2020, JAMA neurology,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
August 2022, Hematological oncology,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
June 2021, JAMA neurology,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
January 2022, Frontiers in immunology,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
June 2021, Neuro-oncology practice,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
October 2019, AJNR. American journal of neuroradiology,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
June 2021, JAMA neurology,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
December 2022, Current treatment options in oncology,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
November 2022, Journal for immunotherapy of cancer,
Agne Taraseviciute, and Victor Tkachev, and Rafael Ponce, and Cameron J Turtle, and Jessica M Snyder, and H Denny Liggitt, and David Myerson, and Luis Gonzalez-Cuyar, and Audrey Baldessari, and Chris English, and Alison Yu, and Hengqi Zheng, and Scott N Furlan, and Daniel J Hunt, and Virginia Hoglund, and Olivia Finney, and Hannah Brakke, and Bruce R Blazar, and Carolina Berger, and Stanley R Riddell, and Rebecca Gardner, and Leslie S Kean, and Michael C Jensen
April 2024, Neurology,
Copied contents to your clipboard!